title: Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.
abstract: The prevalence of diabetes is growing at epidemic rates in the USA. Diabetic retinopathy develops in a large proportion of patients and is a leading cause of blindness worldwide. Systemic management of diabetic retinopathy has included glycemic, hypertension, and lipid control. Local ophthalmic treatment in the form of focal/grid or panretinal laser photocoagulation has been shown to prevent vision loss in diabetic edema and proliferative diabetic retinopathy, respectively. The introduction of anti-vascular endothelial growth factor for diabetic macular edema and retinopathy has provided clinicians with improved clinical outcomes with potentially less damaging effects than laser.
authors.affiliation: California Retina Consultants and Research Foundation, 525 East Micheltorena Street, Suite A, Santa Barbara, CA, 93103, USA. ddhoot@yahoo.com.
authors.forename: Dilsher S
authors.initials: DS
authors.lastname: Dhoot
authors.affiliation: California Retina Consultants and Research Foundation, 525 East Micheltorena Street, Suite A, Santa Barbara, CA, 93103, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Avery
mesh_terms: D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D017075:Laser Coagulation; D008269:Macular Edema / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D042461:Vascular Endothelial Growth Factor A
keywords: Aflibercept; Bevacizumab; DME; Diabetes; Diabetic macular edema; Diabetic retinopathy; Ranibizumab